Stimdia Medical

Stimdia Medical announced recently that it completed the initial closing of a $16 million tranche of its Series B financing round.

Solas Bioventures led the financing round, while new strategic partners and existing investors Draper Triangle Ventures also contributed funding.

Minneapolis-based Stimdia designed its pdSTIM system to offer a tool for addressing high-risk patients, including those with COVID-19, by providing a minimally invasive neurostimulation solution to awaken and recondition the diaphragm. The platform facilitates the weaning of patients suffering from ventilator-induced diaphragmatic dysfunction (VIDD) who are on mechanical ventilation for 96 hours or more and who have failed at least two weaning attempts.

“This funding provides us with the resources needed to support the initiation and completion of our planned FDA pivotal study that will be focused on demonstrating how our technology can strengthen the diaphragm, thereby enabling ear…

Stimdia Medical announced today that it received FDA breakthrough device designation for its pdSTIM system.

Minneapolis-based Stimdia’s pdSTIM system is designed to offer a tool in addressing high-risk patients, including those with COVID-19, by providing a minimally invasive neurostimulation solution to awaken and recondition the diaphragm, according to a news release.

The platform facilitates the weaning of patients suffering from ventilator-induced diaphragmatic dysfunction (VIDD) who are on mechanical ventilation for 96 hours or more and who have failed at least two weaning attempts.

Stimdia’s pdSTIM system is currently offered for investigational use only and is not for sale in any country.

“Receiving FDA breakthrough device designation for the pdSTIM system will help prioritize the process for obtaining regulatory authorization in the U.S.,” Stimdia Medical GM Tim Miller said in the release. “Over 40% of ICU admissions in the U.S…